Ricerc@Sapienza

BACKGROUND: BK virus (BKV) infection represents a potentially dreadful complication after kidney transplantation (KT). When BK viremia is detected, the best therapeutic approach remains not entirely clarified. Critical elements of BK viremia treatment are immunosuppression minimization and introduction of drugs like leflunomide, everolimus, and fluoroquinolones. The study aimed to analyze the results of the BK viremia management in 2 collaborative Italian centers.

Background: Antiretroviral therapy (ART) can suppress the HIV-1 replication but is not able to eradicate the virus due to the existence of viral reservoirs. Optimal virological suppression remains often an ideal goal since some patients may show persistent plasma residual viremia (RV). To date, it is unclear if RV may be regarded as an indication of the potency and tolerability of the regimen, adherence, drug resistance, and pharmacokinetics. Recent studies have shown that other factors, closely related to host,